Karex Berhad (KLSE:KAREX) Full Year 2024 Results
Key Financial Results
- Revenue: RM507.8m (down 4.6% from FY 2023).
- Net income: RM23.4m (up 124% from FY 2023).
- Profit margin: 4.6% (up from 2.0% in FY 2023). The increase in margin was driven by lower expenses.
- EPS: RM0.022 (up from RM0.01 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Karex Berhad EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.1%.
The primary driver behind last 12 months revenue was the Sexual Wellness segment contributing a total revenue of RM463.3m (91% of total revenue). Notably, cost of sales worth RM336.6m amounted to 66% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to RM70.7m (48% of total expenses). Explore how KAREX's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 5.3% p.a. on average during the next 2 years, compared to a 8.9% growth forecast for the Personal Products industry in Asia.
Performance of the market in Malaysia.
The company's share price is broadly unchanged from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Karex Berhad's balance sheet and an in-depth analysis of the company's financial position.
Valuation is complex, but we're here to simplify it.
Discover if Karex Berhad might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KLSE:KAREX
Karex Berhad
An investment holding company, manufactures and sells condoms in Malaysia.
Excellent balance sheet with reasonable growth potential.